Triple Therapy in Type 2 Diabetes: Insulin Glargine or Rosiglitazone Added to Combination Therapy of Sulfonylurea Plus Metformin in Insulin-Naïve Patients

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Diabetes Care

• Publication date

  2006-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/dc06-1295PMID 16505505
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Triple Therapy in Type 2 Diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients

  2007cited by this paper
• Insulin therapy in people who have dysglycemia and type 2 diabetes mellitus: can it offer both cardiovascular protection and beta-cell preservation?

  2005cited by this paper
• Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

  2005cited by this paper
• What to do when two oral agents fail to control type 2 diabetes--a matter of opinion or a matter of fact?

  2004cited by this paper
• Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report.

  2004cited by this paper
• Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

  2004cited by this paper
• Triple therapy: definitions, application, and treating to target.

  2004cited by this paper
• Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial.

  2004cited by this paper
• The burden of treatment failure in type 2 diabetes.

  2004cited by this paper
• Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial.

  2004cited by this paper
• The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

  2003influential reference
• Effect of thiazolidinediones on body weight in patients with diabetes mellitus.

  2003cited by this paper
• Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis.

  2003cited by this paper
• Textbook of type 2 diabetes

  2003cited by this paper
• MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

  2003cited by this paper
• Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).

  2002cited by this paper
• Oral antihyperglycemic therapy for type 2 diabetes: scientific review.

  2002cited by this paper
• Potential short-term economic benefits of improved glycemic control: a managed care perspective.

  2001cited by this paper
• The Effect of a Thiazolidinedione Drug, Troglitazone, on Glycemia in Patients with Type 2 Diabetes Mellitus Poorly Controlled with Sulfonylurea and Metformin: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

  2001cited by this paper
• Effect of improved glycemic control on health care costs and utilization.

  2001cited by this paper
• Insulin Treatment in Type 2 Diabetes

  2001cited by this paper
• Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

  1999cited by this paper
• Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49)

  1999cited by this paper
• Insulin treatment for type 2 diabetes.

  1998cited by this paper
• Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus.

  1998cited by this paper
• The Cost to Health Plans of Poor Glycemic Control

  1997cited by this paper
• Acute Effects of Insulin in the Control of VLDL Production in Humans: Implications for the insulin-resistant state

  1996cited by this paper
• Safety and Efficacy of Normalizing Fasting Glucose With Bedtime NPH Insulin Alone in NIDDM

  1995cited by this paper
• Insulin Therapy Induces Antiatherogenic Changes of Serum Lipoproteins in Noninsulin‐Dependent Diabetes

  1988cited by this paper

• Response to insulin glargine 100 U/mL treatment in newly-defined subgroups of type 2 diabetes: Post hoc pooled analysis of insulin-naïve participants from nine randomised clinical trials.

  2023cites this paper
• Distribution and characteristics of newly-defined subgroups of type 2 diabetes in randomised clinical trials: post hoc cluster assignment analysis of over 12,000 study participants.

  2022cites this paper
• Scientific advisory on nocturnal hypoglycemia in insulin-treated patients with diabetes: Recommendations from Indian experts.

  2022cites this paper
• Features of postoperative therapy in patients with type ІІ diabetes

  2020cites this paper
• Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase‐4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24‐week, open‐label, controlled trial (STOP‐OB)

  2020cites this paper
• Effects of basal insulin on lipid profile compared to other classes of anti-hyperglycaemic agents in type 2 diabetic patients.

  2020cites this paper
• Fiches cliniques

  2019cites this paper
• Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors.

  2019cites this paper
• Multiple Antihyperglycemic Drug Use is Associated with Undernutrition Among Older Adults with Type 2 Diabetes Mellitus: A Cross-Sectional Study

  2019cites this paper
• Titration of insulin glargine 100 U/mL when added to oral antidiabetic drugs in patients with type 2 diabetes: results of the TOP-1 real-world study

  2019cites this paper
• When basal insulin is not enough: A dose–response relationship between insulin glargine 100 units/mL and glycaemic control

  2019cites this paper
• Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.

  2019cites this paper
• Triple and Quadruple Combination Therapy in Type 2 Diabetes: How Rational is the Approach?

  2019cites this paper
• Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study

  2019cites this paper
• Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2018cites this paper
• Rationale and Design of the STOP-OB Study for Evaluating the Effects of Tofogliflozin and Glimepiride on Fat Deposition in Type 2 Diabetes Patients Treated with Metformin/DPP-4 Inhibitor Dual Therapy

  2018cites this paper
• Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice

  2018cites this paper
• Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2018cites this paper
• CONTROVERSIES IN TREATING DIABETES

  2018cites this paper
• Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus

  2018cites this paper
• Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial

  2017cites this paper
• Association of glucagon‐like peptide‐1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system

  2017cites this paper
• Cognitive impairment in diabetes and poor glucose utilization in the intracellular neural milieu.

  2017cites this paper
• Hypoglycemia: a review of definitions used in clinical trials evaluating antihyperglycemic drugs for diabetes

  2017cites this paper
• Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus

  2017cites this paper
• Safe and pragmatic use of sodium–glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement

  2017cites this paper
• The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL

  2017cites this paper
• Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat‐to‐target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes

  2017cites this paper
• Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

  2017cites this paper
• Comparison of cardiovascular and metabolic outcomes in people with type 2 diabetes on insulin versus non-insulin glucose-lowering therapies (GLTs): A systematic review and meta-analysis of clinical trials.

  2016influential citation
• Complementary glucagonostatic and insulinotropic effects of DPP-4 inhibitors in the glucose-lowering action in Japanese patients with type 2 diabetes

  2016cites this paper
• chorego – stanowisko American Diabetes Association ( ADA ) i European Association for the Study of Diabetes ( EASD )

  2016cites this paper
• Glycemic control and adherence to basal insulin therapy in Taiwanese patients with type 2 diabetes mellitus

  2016cites this paper
• NUEVOS FÁRMACOS EN DIABETES MELLITUS

  2016cites this paper
• A patient-centric approach to optimise insulin therapy in Asia.

  2016cites this paper
• COMPARATIVE EFFECTIVENESS OF MULTI ORAL ANTIDIABETIC DRUGS VERSUS INSULIN THERAPY FOR GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS

  2016cites this paper
• Triple therapy combinations for the treatment of type 2 diabetes - A network meta-analysis.

  2016cites this paper
• Pharmacologic Therapy of Type 2 Diabetes.

  2016cites this paper
• Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials

  2016cites this paper
• Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial

  2016cites this paper
• Basal Insulin Initiation in Elderly Patients with Type 2 Diabetes in Taiwan: A Comparison with Younger Patients *

  2015cites this paper
• A study of the descriptive epidemiology and clinical effectiveness of treatment for type 2 diabetes using routine general practice data

  2015cites this paper
• Triple therapy in type 2 diabetes; a systematic review and network meta-analysis

  2015influential citation
• How much is too much? Outcomes in patients using high‐dose insulin glargine

  2015cites this paper
• Benefits of timely basal insulin control in patients with type 2 diabetes.

  2015cites this paper
• Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus

  2015cites this paper
• Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial

  2015cites this paper
• Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta‐analysis

  2015cites this paper
• Efficacy of Some Combination Regimens of Oral Hypoglycaemic Agents in Type 2 Diabetes Mellitus Patients

  2015cites this paper
• Type 2 Diabetes Treatment Recommendations Update: Appropriate Use of Dipeptidyl Peptidase-4 Inhibitors

  2014cites this paper
• Diabetes duration and the efficacy and safety of insulin glargine versus comparator treatment in patients with type 2 diabetes mellitus.

  2014cites this paper
• A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 Diabetes.

  2014cites this paper
• Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials.

  2014cites this paper
• Efficacy and Risk of Hypoglycemia With Use of Insulin Glargine or Comparators in Patients With Cardiovascular Risk Factors

  2014cites this paper
• Comparison of three algorithms for initiation and titration of insulin glargine in insulin‐naive patients with type 2 diabetes mellitus (既往从未使用过胰岛素的2型糖尿病患者使用三种不同的启用与滴定甘精胰岛素剂量方案的比较)

  2014cites this paper
• Population‐based incidence of diabetes in Australian youth aged 10–18 yr: increase in type 1 diabetes but not type 2 diabetes

  2014cites this paper
• Treatment Satisfaction with Insulin Glargine in Insulin-Naïve Type 2 Diabetes Patients—A Hong Kong Based Registry

  2014cites this paper
• Achieving glycaemic targets with basal insulin in T2DM by individualizing treatment

  2014cites this paper
• Weight Change in Patients with Type 2 Diabetes Starting Basal Insulin Therapy: Correlates and Impact on Outcomes

  2014cites this paper
• Outcomes and Treatment Patterns of Adding a Third Agent to 2 OADs in Patients with Type 2 Diabetes

  2014influential citation
• Biphasic insulin aspart 30 improved glycemic control in Chinese patients with type 2 diabetes poorly controlled on oral glucose‐lowering drugs: a subgroup analysis of the A1chieve study

  2014cites this paper
• Global guideline for type 2 diabetes.

  2014cites this paper
• Influence of Baseline Glycemia on Outcomes With Insulin Glargine Use in Patients Uncontrolled on Oral Agents

  2014cites this paper
• Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

  2014cites this paper
• Comparison between the Therapeutic Effect of Metformin, Glimepiride and Their Combination as an Add-On Treatment to Insulin Glargine in Uncontrolled Patients with Type 2 Diabetes

  2014cites this paper
• Chapitre 25 – Fiches cliniques

  2014cites this paper
• Efficacy of structured education in patients with type 2 diabetes mellitus receiving insulin treatment (结构化教育对接受胰岛素治疗的2型糖尿病患者的效果)

  2014cites this paper
• The impact of adherence to medical recommendations (compliance) on incidence of hypoglycemia in diabetic patients treated in outpatient clinic

  2013cites this paper
• Standard and Novel Treatment Options for Metabolic Syndrome and Diabetes Mellitus

  2013cites this paper
• Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus

  2013cites this paper
• Efficacy and Safety of Insulin Glargine Compared to Other Interventions in Younger and Older Adults: A Pooled Analysis of Nine Open-Label, Randomized Controlled Trials in Patients with Type 2 Diabetes

  2013cites this paper
• Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs

  2013cites this paper
• Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient‐level analysis of 12 studies

  2013cites this paper
• Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo‐controlled 54‐week trial in patients with type 2 diabetes (一项为期54周的对持续使用二甲双胍与罗格列酮联合治疗的2型糖尿病患者加用西格列汀治疗的有效性与安全性的随机安慰剂对照研究) *

  2013cites this paper
• Current role of short‐term intensive insulin strategies in newly diagnosed type 2 diabetes (短期胰岛素强化治疗策略对初诊2型糖尿病患者的作用)

  2013cites this paper
• Effect of gender on treatment outcomes in type 2 diabetes mellitus.

  2013cites this paper
• Complementing Insulin Therapy to Achieve Glycemic Control

  2013cites this paper
• Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes

  2013cites this paper
• TRIPLE ORAL ANTIDIABETIC OR METFORMIN-BASAL INSULIN COMBINATION : TESTING TWO DIFFERENT APPROACHES OF CONSENSUS ALGORITHM IN ADJUSTING ANTIDIABETIC THERAPY . AN OPEN-LABEL , RANDOMIZED STUDY

  2013cites this paper
• Exenatide Once Weekly Versus Daily Basal Insulin as Add-on Treatment to Metformin With or Without a Sulfonylurea: A Retrospective Pooled Analysis in Patients With Poor Glycemic Control

  2013cites this paper
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2012cites this paper
• Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis

  2012influential citation
• Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes

  2012cites this paper
• Fasting plasma glucose 6–12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis

  2012cites this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cites this paper
• The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide

  2012cites this paper
• Optimal management of type 2 diabetes: the evidence

  2012cites this paper
• Insulin therapy in type 2 diabetes mellitus.

  2012cites this paper
• Thiazolidinediones and PPARγ agonists: time for a reassessment.

  2012cites this paper
• 2型糖尿病患者におけるDPP-4阻害薬を用いた多剤併用療法の実施状況と短期治療成績(JDDM-29)

  2012cites this paper
• Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose‐lowering therapy in people with type 2 diabetes: an observational study

  2012cites this paper
• Análogos de insulina: relevancia clínica y perspectivas futuras Insulin analogues: clinical relevance and future perspectives

  2012cites this paper
• Rosiglitazone

  2012cites this paper
• Diabetes: glycaemic control in type 2 (drug treatments).

  2012cites this paper
• Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis

  2012cites this paper
• Insulin Analogs and Glycosylated Hemoglobin Target of Less Than 7% in Type 2 Diabetes: A Systematic Review of Randomized Trials

  2011cites this paper
• Triple oral fixed‐dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study‐II)

  2011cites this paper
• An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia

  2011cites this paper
• Effectiveness of adding vildagliptin to the treatment of diabetic patients nonresponsive to the combination of metformin and a sulphonylurea.

  2011cites this paper
• Pharmacological management of type 2 diabetes: the potential of incretin‐based therapies

  2011cites this paper